Halozyme Therapeutics Aktie
WKN: A0DLHS / ISIN: US40637H1095
11.08.2014 23:09:38
|
Halozyme Therapeutics Q2 Loss Narrows - Quick Facts
(RTTNews) - Halozyme Therapeutics, Inc. (HALO) posted fourth-quarter net loss of $16.3 million or $0.13 per share, narrower than $22.9 million or $0.20 per share in the year-ago period.
On average, eight analysts polled by Thomson Reuters expected the company to report a loss of $0.14 per share. Analysts' estimates typically exclude special items.
Total revenues for the latest second quarter rose to $18.39 million from $14.45 million in the comparable quarter last year, while seven analysts had consensus revenue estimate of $13.71 million for the quarter.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Halozyme Therapeutics Inc.mehr Nachrichten
17.02.25 |
Ausblick: Halozyme Therapeutics vermeldet Zahlen zum jüngsten Quartal (finanzen.net) | |
30.10.24 |
Ausblick: Halozyme Therapeutics öffnet die Bücher zum abgelaufenen Quartal (finanzen.net) |
Analysen zu Halozyme Therapeutics Inc.mehr Analysen
15.11.24 | Halozyme Therapeutics Neutral | JP Morgan Chase & Co. |
Aktien in diesem Artikel
Halozyme Therapeutics Inc. | 50,34 | -9,62% |
|